Cardiomyotomy Laparoscopic — Cost, Top Hospitals & Success Rates | MyMedicPlus

Laparoscopic Heller cardiomyotomy (LHM) is a minimally invasive surgical procedure that divides the muscular fibres of the lower oesophageal sphincter (LOS) and a portion of the gastric cardia, permanently reducing the elevated sphincter pressure that characterises achalasia cardia and related oesophageal motility disorders. The procedure was originally described as an open operation by Ernst Heller in 1913; the laparoscopic approach, developed in the 1990s, has now completely replaced open surgery at experienced centres due to equivalent efficacy, shorter hospital stay, faster recovery, and lower morbidity.

Achalasia cardia results from selective degeneration of inhibitory ganglion cells (nitric oxide-producing neurons) in Auerbach's myenteric plexus — the cause of which is unknown but may be immune-mediated following viral triggering in genetically susceptible individuals. The pathophysiological consequence is loss of lower oesophageal sphincter relaxation during swallowing (failure of the LOS to open) combined with absent or aperistaltic oesophageal body contractions (failure of food to be propelled distally). The oesophagus above the obstruction progressively dilates, and patients experience progressive dysphagia to both solids and liquids, regurgitation of undigested food, heartburn, chest pain, weight loss, and nocturnal aspiration with coughing and aspiration pneumonia.

LHM is performed through 5 small laparoscopic ports (5–10 mm) under general anaesthesia. The operation involves mobilisation of the gastro-oesophageal junction, division of the circular and longitudinal muscle layers of the lower 6–8 cm of oesophagus and upper 2–3 cm of gastric cardia using electrocautery or harmonic scalpel, careful preservation of the underlying mucosa, and — in most contemporary practice — addition of a partial anterior fundoplication (Dor fundoplication) to reduce the risk of post-operative gastro-oesophageal reflux disease (GORD), which is the primary long-term complication of myotomy without fundoplication.

The primary indication for laparoscopic cardiomyotomy is achalasia cardia (idiopathic achalasia), classified into three subtypes by Chicago Classification v4.0 based on high-resolution manometry (HRM) oesophageal pressure topography: Type I (classic achalasia — absent peristalsis, minimal pressurisation), Type II (with pan-oesophageal pressurisation — best prognosis after any treatment), and Type III (spastic achalasia — premature/spastic contractions — historically most difficult to treat with LHM as the spastic segment may extend beyond the myotomy).

Other indications include Chagas disease achalasia (endemic in South America — caused by Trypanosoma cruzi infection destroying myenteric plexus neurons, with similar manometric findings to idiopathic achalasia), idiopathic diffuse oesophageal spasm with impaired LOS relaxation, and oesophagogastric junction outflow obstruction on manometry. Secondary or pseudoachalasia — caused by an infiltrating tumour at the GEJ (most commonly gastric adenocarcinoma or pancreatic carcinoma) or following fundoplication — must be excluded before myotomy, as LHM of a malignant stricture is inappropriate and delays cancer diagnosis. Endoscopy, CT scanning, and endoscopic ultrasound are required to rule out pseudoachalasia when symptoms are recent onset (less than 1 year) or in patients over 60 years.

Patients with confirmed achalasia on oesophageal manometry (high-resolution preferred) and barium swallow, without evidence of pseudoachalasia, who have adequate functional status for general anaesthesia are candidates for LHM. There is no absolute age restriction — the procedure is performed safely in children, adults, and elderly patients. Endoscopy must be performed to exclude malignancy and to characterise the degree of oesophageal dilation.

In end-stage achalasia (sigmoid oesophagus — massively dilated oesophagus with a sigmoid shape on barium swallow, typically after years of untreated disease), LHM alone may not be adequate, and oesophagectomy or subtotal oesophageal resection with gastric pull-up is sometimes considered. Prior treatment with multiple pneumatic dilations or failed anterior myotomy (through the POEM approach, which approaches from the posterior submucosal tunnel) can still be managed by LHM but requires a technically more demanding procedure with higher mucosal perforation risk. Prior Botox injection to the LOS — a temporary measure — causes perisphincteric fibrosis that increases the technical difficulty of myotomy. Morbid obesity does not contraindicate laparoscopic cardiomyotomy but may require ergonomic adaptations.

Standard laparoscopic Heller myotomy with Dor (anterior 180-degree partial) fundoplication is the most widely performed approach. The myotomy extends 6 cm onto the oesophagus and 2–3 cm onto the gastric cardia, completely dividing all circular muscle fibres. The Dor fundoplication — where the gastric fundus is sutured over the exposed oesophageal mucosa anteriorly — provides protection against reflux and prevents the exposed mucosa from forming a diverticulum, and also provides additional perimucosal protection against perforation repair. Toupet posterior fundoplication (270 degrees) is an alternative at some centres, offering effective anti-reflux protection while keeping the myotomy edges open.

Robotic Heller cardiomyotomy offers enhanced three-dimensional visualisation and articulated instrument movement, potentially reducing mucosal perforation rates compared to standard laparoscopy, at the cost of longer operative time and higher equipment cost. POEM (peroral endoscopic myotomy) — an endoscopic procedure where a submucosal tunnel is created from within the oesophagus and the circular muscle is divided from below the mucosa — has emerged as a major alternative to LHM with equivalent or superior dysphagia relief, particularly for Type III achalasia where a longer myotomy is technically feasible. POEM's principal disadvantage is a higher rate of clinically significant GORD (30–50%) due to absence of fundoplication. Pneumatic dilation — balloon dilation of the LOS under fluoroscopic guidance — achieves good symptomatic relief in Type II achalasia (80–90% success) and is the primary treatment in many European centres, though the benefit may not be as durable as LHM.

Laparoscopic Heller myotomy achieves excellent dysphagia relief in approximately 85–90% of patients at 5 years follow-up, with durable long-term results maintained in 70–85% at 10 years. Treatment success is defined as an Eckardt score of 3 or below (a validated symptom severity score incorporating dysphagia, regurgitation, chest pain, and weight loss). Type II achalasia has the highest success rates with any treatment modality; Type III responds better to POEM or extended myotomy than to standard LHM.

A landmark randomised trial published in the New England Journal of Medicine (Boeckxstaens et al., 2011, the European Achalasia Trial) compared laparoscopic cardiomyotomy with pneumatic dilation, demonstrating equivalent efficacy (89% vs 90% success at 2 years, and 84% vs 82% at 5 years), establishing both as first-line treatment options. The Ling long-term series and multiple systematic reviews confirm that LHM provides superior long-term dysphagia relief compared to repeated Botox injections, with botulinum toxin offering only temporary benefit (median durability 6–12 months) and reserved for patients not fit for surgery or endoscopic treatment.

Intraoperative mucosal perforation — breach of the underlying oesophageal mucosa during muscle division — is the most important intraoperative complication, occurring in 1–5% of cases. It is repaired immediately with laparoscopic suture closure; recognised and repaired perforations do not usually affect the final outcome. Unrecognised perforations cause mediastinal contamination, oesophageal leakage, and potentially life-threatening sepsis. Robotic assistance may reduce perforation rates by improving visualisation of the mucosal plane.

Gastro-oesophageal reflux disease (GORD) is the most significant long-term complication, occurring in 10–25% of patients with Dor fundoplication versus 40–60% without anti-reflux procedure. Untreated GORD after myotomy can cause oesophagitis, Barrett's oesophagus, and eventually peptic stricture — potentially worsening dysphagia. Proton pump inhibitor therapy and post-operative pH monitoring guide management. Incomplete myotomy — insufficient division of muscle fibres, particularly at the gastric extension — results in persistent dysphagia or early symptomatic recurrence. Bleeding requiring conversion to open surgery occurs in below 1% of laparoscopic cases. Conversion to open surgery occurs in 1–3% of cases due to bleeding, perforation, or dense adhesions from previous upper abdominal surgery.

Hospital stay after laparoscopic Heller cardiomyotomy is typically 2–3 days. Patients begin clear liquids on the evening of the operation, progress to pureed food by day 2, and follow a soft diet for 2–4 weeks before returning to normal food. The laparoscopic port sites heal quickly, with return to light activities within 1–2 weeks and full activity (including non-contact sports) within 3–4 weeks. A low-residue soft diet is advised for 4 weeks to allow the myotomy site to heal without food impaction above the gastro-oesophageal junction.

Post-operative assessment includes an Eckardt symptom score at 3 and 12 months. Oesophageal function is reassessed with timed barium swallow at 3–6 months to document oesophageal emptying. Ambulatory 24-hour pH-impedance monitoring at 3–6 months documents any pathological acid reflux and guides proton pump inhibitor therapy intensity. Endoscopy at 1 year evaluates the oesophageal mucosa for oesophagitis and Barrett's change, and confirms the appearance of the myotomy. Annual or biennial surveillance thereafter is recommended given the increased risk of oesophageal squamous cell carcinoma in long-standing achalasia.

In the United States, laparoscopic Heller cardiomyotomy with fundoplication costs $20,000–$50,000 including surgeon fees, anaesthesia, operating room, and 2–3 day hospital stay. POEM performed at an academic endoscopy centre costs a similar amount ($15,000–$40,000). For uninsured patients or those with high co-pay insurance plans, out-of-pocket costs represent a major barrier.

India is an excellent destination for laparoscopic Heller cardiomyotomy, with an established tradition of laparoscopic upper GI surgery at dedicated centres. The procedure at JCI-accredited hospitals (Apollo, Fortis, Medanta, Asian Institute of Gastroenterology in Hyderabad) costs $3,000–$6,000 all-inclusive. Thailand (Bumrungrad, Bangkok Hospital) offers the procedure for $4,000–$8,000. Turkey and Malaysia offer costs of $3,500–$7,000 with comparable outcomes. Savings of 75–85% compared to US prices are achievable while receiving care from surgeons with high-volume experience in laparoscopic upper GI procedures.

Pneumatic dilation (PD) is a major non-surgical alternative, particularly for Type II achalasia where it achieves results equivalent to LHM (90% short-term, 80% 5-year success in multiple series). PD involves an endoscopic procedure under fluoroscopic guidance where a controlled radial-expansion balloon (30 or 35 mm) is inflated across the LOS to disrupt the circular muscle fibres. Perforation risk is approximately 2–3%. Multiple dilations may be required for sustained benefit. PD followed by LHM for treatment failures is a recognised treatment algorithm.

Botulinum toxin (Botox) injection into the LOS via upper endoscopy provides temporary LOS relaxation by blocking acetylcholine release from excitatory neurons, restoring some sphincter relaxation for 6–12 months. It is not a definitive treatment due to its short duration of action but is appropriate for elderly or frail patients who cannot tolerate surgery or endoscopic treatment, as a temporary measure while planning definitive intervention, or for symptom relief in pseudoachalasia where the underlying malignancy is being treated. Calcium channel blockers (nifedipine) and nitrates (isosorbide dinitrate) reduce LOS pressure modestly but are poorly tolerated due to systemic side effects and are used only as bridge therapy. Oesophagectomy is reserved for end-stage sigmoid achalasia or failed multiple prior treatments.